Big data analysis powers the fight against Alzheimer’s

A PNNL technician studies a brain tissue sample.
Photo by Andrea Starr | Pacific Northwest National Laboratory

New research helps explain the progression of Alzheimer’s disease and predicts its severit.

Alzheimer’s disease has always had its puzzles and contradictions. For Pacific Northwest National Laboratory (PNNL) researcher Vladislav Petyuk, whose research on the progressive, age-related disease spans over a decade, some of the struggles have come from studies where “we can only connect the dots a pair at a time.”

Petyuk’s research touches multiple areas in biological and computational science at PNNL. He has produced dozens of publications on Alzheimer’s disease. But now he sees the needle moving in the right direction.

“Over the last 10 years,” Petyuk said, “research has been moving away from a single drug target towards focusing more on the proteins that have a role in cognitive resilience.”

Cognitive resilience is a measure of the brain’s ability to continue to work even with a high Alzheimer’s disease neuropathology that would normally produce the hallmark dementia. This means that, in some people, the brain shows the symptoms of the disease, but it does not impact the person’s ability to function. What makes some brains sensitive, and some resilient, is an open question.

Petyuk recently collaborated with a multi-institutional team in a study that examined a large Alzheimer’s disease cohort of over 1800 people. The researchers drew on previously collected blood samples and brain tissue, along with large-scale data analysis to search for central themes in early identification, prevention, and treatment of the disease.

The research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. Further, the findings outline a multilevel biological classification system that predicts disease severity and future neurological symptoms. “Assessment of a patient’s brain and blood proteins, and other biological molecules, reveal patterns that can then be targeted for tailored intervention,” said Petyuk.

The discovery is particularly timely, as November is Alzheimer’s disease awareness month. In the United States, 5.4 million people aged 65 and older live with Alzheimer’s disease. The numbers grow annually as the population ages.

The right tools, at the right time, in the right place

These types of large-scale studies, exploring proteins and protein-related data are often called proteomics studies.

Proteomics research at PNNL involves, among other things, the ability to analyze very large data sets. Examining, identifying, and discovering proteins can answer specific biological questions about their role in the disease, as well as identifying multiple new drug targets in the fight against Alzheimer’s disease and related dementias.

Leveraging PNNL’s advanced proteomics platform capabilities to answer these big questions to fill in the knowledge gaps, Petyuk has contributed to six published research studies in this year alone. The work validates the power of discovery in the proteomics platform at PNNL, as well as the power in the collaborative efforts of Petyuk’s colleagues from all over the world.

Putting together pieces of the Alzheimer’s puzzle

Some symptoms of the disease are due to the misfolding of proteins. Proteins need to have a specific shape to function correctly, and much like baking a cake, changing the recipe can result in a misshapen product. Alzheimer’s disease can cause protein recipes to change. This research adds to the emerging body of work on proteins involved in cognitive decline that are associated with the disease. These proteins may indicate potential new targets for drug therapies.

Even with such a large body of work, the puzzle still only gets put together one piece at a time, with lots of smaller parts that make sense, but a yet-to-be-discovered larger view. Petyuk, along with team lead Yasser Iturria-Medina at the Montreal Neurological Institute of the McGill University, continue work that adds to our understanding of a complex and devastating disease. This promises new discoveries, and new pieces to add to the puzzle of Alzheimer’s disease.

About PNNL

Pacific Northwest National Laboratory draws on its distinguishing strengths in chemistry, Earth sciences, biology and data science to advance scientific knowledge and address challenges in sustainable energy and national security. Founded in 1965, PNNL is operated by Battelle for the Department of Energy’s Office of Science, which is the single largest supporter of basic research in the physical sciences in the United States. DOE’s Office of Science is working to address some of the most pressing challenges of our time. For more information, visit https://energy.gov/science. For more information on PNNL, visit PNNL’s News Center. Follow us on Twitter, Facebook, LinkedIn and Instagram.

By Rita Steyn

Journal: Science Advances
DOI: 10.1126/sciadv.abo6764
Article Title: Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer’s disease progression and heterogeneity
Article Publication Date: 13-Nov-2022

Media Contact

Greg Koller
DOE/Pacific Northwest National Laboratory
greg.koller@pnnl.gov
Office: 509-372-4864

Media Contact

Greg Koller
DOE/Pacific Northwest National Laboratory

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Toward practical quantum optics: multiphoton qubits from LNOI

New research demonstrates feasibility of photon-number doubling with a lithium-niobate-on-insulator (LNOI) platform. Can quantum optics be used for practical applications? A lot depends on whether a large number of photons…

Could space dust help protect the earth from climate change?

On a cold winter day, the warmth of the sun is welcome. Yet as humanity emits more greenhouse gases, the Earth’s atmosphere traps more and more of the sun’s energy,…

New way to reduce progression of diabetic kidney disease discovered

Study could help the 4.8 million people in the UK with diabetes. A new way to reduce progression of diabetic kidney disease, affecting 40% of people with diabetes, has been…

Partners & Sponsors